Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | F3 | P13726 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14001979 | 0.92 | ALDH1A1 (0.38) | ALDH1A1GAAMEN1HTTKMT2A | |
| SCHEMBL13148281 | 0.86 | KMT2A (0.46) | ALDH1A1GAAMEN1HTTKMT2A | |
| SCHEMBL5648710 | 0.86 | GAA (0.46) | ALDH1A1GAAKDM4EMAPTHPGD | |
| SCHEMBL78186 | 0.85 | HTT (0.40) | ALDH1A1GAAMEN1HTTKMT2A | |
| SCHEMBL24453525 | 0.82 | HTT (0.38) | ALDH1A1GAAMEN1HTTKMT2A | |
| SCHEMBL7193144 | 0.79 | HTT (0.42) | ALDH1A1GAAHTTKMT2AKDM4E | |
| SCHEMBL13568624 | 0.77 | ALDH1A1 (0.34) | ALDH1A1GAAMEN1HTTKMT2A | |
| SCHEMBL3737768 | 0.75 | ALDH1A1 (0.33) | ALDH1A1GAAMEN1HTTKMT2A | |
| SCHEMBL21298584 | 0.75 | HTT (0.37) | ALDH1A1GAAMEN1HTTKMT2A | |
| SCHEMBL23071653 | 0.75 | RAB9A (0.35) | ALDH1A1GAAMEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234494-A1 | Reversibly thermochromic compositions | CIBA CORPORATION | 2010-09-16 | — | — | US | disclosed |
| US-20100048774-A1 | STABILIZER MIXTURES | GUGUMUS FRANCOIS | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234494-A1 | Reversibly thermochromic compositions | CRY1, REL, CRY2 | ALDH1A1 3798/4885GAA 4878/4885MEN1 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.